What's behind AstraZeneca's latest 9.4% stock pullback?

Traders Union
All News
Financial News
AstraZeneca drops 9.41% to GBX12,900

Highlights

AstraZeneca shares fell sharply after its Phase III CARDIO-TTRansform trial for Wainua missed the primary efficacy endpoint, hitting future pipeline prospects.
The company bolstered its late-stage pipeline by securing ex-China rights to experimental COPD therapy TQC3721 through a significant deal with Sino Biopharmaceutical.
Technical signals show AZN trading below key moving averages, with high volatility and a forecasted GBX12,630–14,398 range over the next few days.

Failed drug trial and new licensing deal reshape pipeline outlook

The principal driver of today's move was the announcement that the Phase III CARDIO-TTRansform trial of Wainua (eplontersen) did not achieve its primary efficacy endpoint in treating transthyretin-mediated amyloid cardiomyopathy, curbing future pipeline revenue potential and adding pressure to AstraZeneca's development outlook, according to Tipranks. Additionally, AstraZeneca signed a high-value exclusive licensing deal with Sino Biopharmaceutical for ex-China rights to the experimental COPD treatment TQC3721, a move that expands its late-stage therapeutic pipeline, as reported by Seekingalpha. The company has also made progress toward expanding access to Enhertu in England and Wales and initiated a strategic genomics partnership with Helix, though these developments are secondary in the context of today's sharp downdraft.

Technical resistance and mixed momentum amid heightened volatility

Technically, AZN trades below the MA-20 at GBX14,231 and MA-50 at GBX14,245 on the h1 timeframe, along with the MA-200 at GBX13,768 on the daily chart. The Ichimoku Kijun at GBX14,227 acts as immediate resistance. On the h1 timeframe, the Moving Average Convergence Divergence (MACD) shows a Sell signal and the Average Directional Index (ADX) is Neutral, indicating weak directional conviction. The Relative Strength Index (RSI) is at 49.49 with a Sell signal, the Commodity Channel Index (CCI) is Neutral, and Stochastic RSI signals a Buy. Bull/Bear Power (BBP) points to Overbought conditions, while the Awesome Oscillator remains Neutral. Oscillators as a group present mixed signals, reflecting a divergence between short-term buyer interest and broader weak momentum amid high volatility.

Sideways bias prevails as breakout risk shapes short-term moves

Looking ahead to the next 2–3 trading days, AZN is expected to trade within a range of GBX12,630 to GBX14,398. The probability of an upward move is currently estimated at 61%. The baseline scenario remains sideways trading within this band, while a move above GBX14,227 could open the way for additional gains. Conversely, renewed selling would likely intensify if price action breaks below the lower support boundary at GBX12,630.

Viktoras Karapetjanc, Traders Union expert, sees today's sharp decline as an overreaction to the Wainua trial setback. He believes AstraZeneca's fundamentals remain solid thanks to continued pipeline development and recent strategic deals. Macro and sentiment pressures are present, but long-term growth drivers are intact. He expects the market to stabilize within the current trading range. "Despite disappointment today, I see the current dip as a potential long-term entry for fundamentally strong investors."

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.